The Lancet. OncologyHumansCarcinomaNon-Small-Cell LungMaleFemale
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.
Yi-Long Wu, Yu Yao, Jin-Ji Yang, Lin Wu, Wei Zhang, Ying Wang, Hai-Peng Xu, Yong Song, Yan Zhang, Jun Zhao, Jing-Hua Chen, Zhe-Hai Wang, Qi-Ming Wang, Jie Hu, Xing-Ya Li
Published: 202610.1016/S1470-2045(25)00594-7
Abstract
BACKGROUND: MET amplification is recognised as a de novo driver alteration in non-small-cell lung cancer (NSCLC) but treatment responses with existing MET inhibitors remain largely unsatisfactory. We aimed to investigate the antitumour activity and s…
Preview only. Read the full abstract at the source